Biomarker-Driven Maintenance Reshapes Outcomes in Gynecologic Cancers

Advancements in the treatment of gynecologic cancers, particularly ovarian and endometrial, have increasingly focused on personalized maintenance therapies guided by molecular biomarkers like proficient mismatch repair and homologous recombination deficiency. As of early 2026, the clinical landscape is defined by a shift toward targeted interventions designed to delay recurrence and improve long-term survival in high-risk populations.

Erin Crane, MD, MPH, gynecologic oncologist at the Atrium Health Levine Cancer Institute, emphasizes that these "biomarker-driven" approaches are critical. By tailoring maintenance to a patient's specific molecular signatures, clinicians can finally bridge the gap between initial response and long-term remission in some of the most challenging gynecologic diagnoses.